What Made Mikhail Blagosklonny Start Oncotarget

Mikhail Blagosklonny wanted Oncotarget to be a success. He wanted to see it be successful not because it was something he started, but instead because he was making sure he could use it to actually help people. There were so many ways in which the publication was providing a place for people to learn more about treatment and that’s what Mikhail Blagosklonny wanted from the beginning for it. He was sure there would be different things he could do to make it as successful as possible and that translated to him always making things easier on himself and on the different situations he was in.

By the way that Mikhail Blagosklonny was doing business and handling the publication, he felt confident it would be something that would grow and get better for all the people who he was helping. He believed the peer review publication would be able to help the doctors who were using it to make things easier but he also believed their patients would be the ones who got the biggest benefit out of the publication. If doctors knew what they were doing when it came to their patients, they would have a better chance of helping to cure cancer. Read more about Mikhail on Crunchbase.

As long as Mikhail Blagosklonny was running the publication, he felt it was something that would be successful. In fact, he worked hard to make sure that it was successful. There were so many different ways people could benefit from what he was doing and from the options he had available to those who were in need of cancer treatment. It all went back to the way the industry worked and the things Mikhail Blagosklonny was doing to make sure he could help cancer patients. For them to realize what he was doing, they would have to take advantage of the publication.

In addition to the oncologists who became a part of the Oncotarget publication, there were also other doctors who were a part of it. They were trying their best to make sure they could understand the things that were going on and the opportunities they had to be successful. It was how they were making sure they could do things and how they were offering different opportunities to be successful in different areas. For those who were a part of Oncotarget, they found Mikhail Blagosklonny was doing the best he could with the publication.

Read this article about Mikhail at inprogressmag.com.

One of the biggest treatment options the doctors who worked with the publication found was the ability to use anti-aging treatments to help their patients. These were easy for the doctors to obtain and they came with very few side effects. The patients were able to battle the chemotherapy issues and radiation issues once they had the drugs. It helped them make sure they were not producing the wrong type of cells. For the patients, this was a way to actually feel better about what they were doing and how they were getting better after going through the cancer treatment process.  Follow Mikhail on Google Scholar.

Genomic Research: Omar Boraie Makes a Remarkable Gift to the Cancer Fight

On October 21, 2015, Newswise released a story spotlighting cancer research at Rutgers Cancer Institute of New Jersey, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute. The reporting focused on the establishment of the Omar Boraie Chair in Genomic Science. For those who are unfamiliar with endowed chairs, they are widely considered the top standard of continued support for a university that commits to an academic discipline.

In this case, that discipline is cancer research, and the support comes in the form of a $1.5 million pledge from the new Omar Boraie Chair. The article goes on to explain that the chair is named after a New Brunswick developer, Omar Boraie, and is part of a campaign by Rutgers known as the “18 Chair Challenge”, view his crunchbase bio to learn more. The concept is that an anonymous donor will match the $1.5 million donations resulting in a $3 million endowment for each.

For many years, researchers have battled the scourge of cancer seeking to find more effective treatments and hoping to discover what has long been an elusive cure. The research conducted at Rutgers focuses on the relatively new discoveries in the field of Genomics. The study of genes is rapidly changing the approach to cancer diagnosis and treatment.

Understanding cancer on a genetic level allows oncologists to create precise therapies unique to each patient. Breakthroughs in this kind of precision medicine help doctors to become more efficient at classifying types of cancer. They can then more precisely identify and group cancerous cells by similar characteristics. Reaching higher levels of accuracy of genomic identification leads to much better outcomes for sufferers.

One significant result of genomic sequencing; providing greater value in treatment options to those with rare cancers. To this point, these patients were left with little hope because they have had treatment options that at best were limited, and at worst ineffective. The new research at Rutgers is beginning to help even those patients whose cancers are no longer responsive.

Mr. Omar Boraie is hopeful that his family’s pledge will encourage others to do the same. He is no stranger to chemistry, has long been interested in cancer research, and remains dedicated to moving the cancer research forward by developing transnational clinical treatments. The entire article is available here.